Orthocell Announces Gluteal Tendon Publication

- Peer reviewed paper published in the Orthopaedic Journal of Sports Medicine
- 2 year data for Ortho-ATI® in degenerate hip (Gluteal) tendons
- Data shows positive outcomes including reduced pain and increased functionality out to 24 months following Ortho-ATI®
- Results further validate Orthocell’s Ortho-ATI® as a minimally invasive, cost effective and long solution for degenerate, treatment resistant tendons.

Perth, Australia; 27 February 2017: Regenerative medicine company Orthocell is pleased to announce the publication of 2 year data for Ortho-ATI® in degenerate hip (Gluteal) tendons. The paper further supports Orthocell’s Ortho-ATI® as a durable long term solution for degenerate, treatment resistant tendons.

Gluteal tendinopathy is a common and difficult injury to treat, affecting mostly women between the ages of 35 and 65. High levels of dysfunction have been found in people with gluteal tendinopathy who fail conservative treatment including loss of full time employment, higher pain levels and poorer quality of life.

The paper’s objective was to investigate the safety and effectiveness of Ortho-ATI®, specifically in patients with chronic recalcitrant gluteal tendinopathy. Twelve female patients demonstrated a mean duration of symptoms of 33 months (range, 6-144 months), and had failed to respond to existing conservative treatments including physiotherapy and corticosteroid injections.

Chief investigator of the study Dr Greg Janes commented “Gluteal tendinopathy is a common and debilitating injury that is often difficult to treat and this research highlights the exciting potential of Ortho-ATI as a minimally invasive and targeted cellular therapy for degenerate tendon conditions”.

The results demonstrated Orthocell’s Ortho-ATI® therapy significantly improved the clinical outcome of patients with long term gluteal tendon degeneration including reduced pain and increased functionality at 3 months and maintained out to 2 years following a single ultrasound guided injection of Ortho-ATI®.

Orthocell Managing Director Paul Anderson said “The positive data supports the ongoing validation of Ortho-ATI® as a minimally invasive cell therapy to treat tendons that have failed to respond to conservative treatments and adds to the growing body of published data that supports Ortho-ATI as a treatment option for degenerate tendons.

-ENDS-

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au
For more information, please contact:

General enquiries
Paul Anderson
Orthocell Limited, Managing Director
P: +61 8 9360 2888
E: paulanderson@orthocell.com.au

Investor and Media enquiries
Ben Walsh
WE Buchan
P: + 61 411 520 012
E: b Walsh@buchanwe.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.